Characteristics of patients with post–CAR-T progression/death vs ongoing response at last follow-up
| Characteristic . | Ongoing response, n = 230 . | Progression/death, n = 284 . | P value . |
|---|---|---|---|
| No. (%) . | No. (%) . | ||
| Age at CAR-T | 58.5 (21-83) | 59 (18-84) | .42 |
| Female sex | 96 (41.7%) | 113 (39.8%) | .72 |
| Histologic subtype | <.01 | ||
| de novo DLBCL | 142 (62%) | 215 (76%) | |
| tFL | 62 (27%) | 36 (13%) | |
| PMBL | 4 (2%) | 5 (2%) | |
| Richter’s | 9 (4%) | 9 (3%) | |
| Other | 13 (6%) | 19 (7%) | |
| Subtype | .41 | ||
| Non-GCB | 66 (38%) | 131 (43%) | |
| GCB | 107 (62%) | 97 (57%) | |
| Lines of therapy before CAR-T | 2 (1-6) | 3 (1-6) | <.01 |
| LDH elevation at apheresis | 96 (42%) | 161 (57%) | <.01 |
| IPI at apheresis | .02 | ||
| 0-1 | 51 (27%) | 43 (18%) | |
| 2-3 | 113 (60%) | 147 (60%) | |
| 4-5 | 23 (12%) | 55 (22%) | |
| Extranodal disease at apheresis | 130 (60%) | 208 (75%) | <.01 |
| CNS disease at apheresis | 10 (4%) | 22 (8%) | .1 |
| Prior allogeneic HCT | 1 (0.4%) | 0 (0) | .45 |
| Prior autologous HCT | 64 (28%) | 75 (26%) | .76 |
| Double hit/double expressor | .01 | ||
| Double hit | 45 (20%) | 36 (13%) | |
| Double expressor | 30 (13%) | 56 (20%) | |
| None | 112 (49%) | 155 (55%) | |
| Unknown | 43 (19%) | 37 (13%) | |
| CAR-T product | .29 | ||
| Axi-cel | 155 (67%) | 175 (62%) | |
| Tisa-cel | 54 (23%) | 84 (30%) | |
| Liso-cel | 21 (9%) | 24 (8%) | |
| BT | 86 (37%) | 152 (54%) | <.01 |
| CRS | 157 (70%) | 185 (64%) | .16 |
| Tocilizumab use | 126 (55%) | 119 (42%) | <.01 |
| ICANS | 108 (47%) | 127 (45%) | .66 |
| Steroid use to treat CAR-T toxicities | 100 (45%) | 128 (47%) | .65 |
| Characteristic . | Ongoing response, n = 230 . | Progression/death, n = 284 . | P value . |
|---|---|---|---|
| No. (%) . | No. (%) . | ||
| Age at CAR-T | 58.5 (21-83) | 59 (18-84) | .42 |
| Female sex | 96 (41.7%) | 113 (39.8%) | .72 |
| Histologic subtype | <.01 | ||
| de novo DLBCL | 142 (62%) | 215 (76%) | |
| tFL | 62 (27%) | 36 (13%) | |
| PMBL | 4 (2%) | 5 (2%) | |
| Richter’s | 9 (4%) | 9 (3%) | |
| Other | 13 (6%) | 19 (7%) | |
| Subtype | .41 | ||
| Non-GCB | 66 (38%) | 131 (43%) | |
| GCB | 107 (62%) | 97 (57%) | |
| Lines of therapy before CAR-T | 2 (1-6) | 3 (1-6) | <.01 |
| LDH elevation at apheresis | 96 (42%) | 161 (57%) | <.01 |
| IPI at apheresis | .02 | ||
| 0-1 | 51 (27%) | 43 (18%) | |
| 2-3 | 113 (60%) | 147 (60%) | |
| 4-5 | 23 (12%) | 55 (22%) | |
| Extranodal disease at apheresis | 130 (60%) | 208 (75%) | <.01 |
| CNS disease at apheresis | 10 (4%) | 22 (8%) | .1 |
| Prior allogeneic HCT | 1 (0.4%) | 0 (0) | .45 |
| Prior autologous HCT | 64 (28%) | 75 (26%) | .76 |
| Double hit/double expressor | .01 | ||
| Double hit | 45 (20%) | 36 (13%) | |
| Double expressor | 30 (13%) | 56 (20%) | |
| None | 112 (49%) | 155 (55%) | |
| Unknown | 43 (19%) | 37 (13%) | |
| CAR-T product | .29 | ||
| Axi-cel | 155 (67%) | 175 (62%) | |
| Tisa-cel | 54 (23%) | 84 (30%) | |
| Liso-cel | 21 (9%) | 24 (8%) | |
| BT | 86 (37%) | 152 (54%) | <.01 |
| CRS | 157 (70%) | 185 (64%) | .16 |
| Tocilizumab use | 126 (55%) | 119 (42%) | <.01 |
| ICANS | 108 (47%) | 127 (45%) | .66 |
| Steroid use to treat CAR-T toxicities | 100 (45%) | 128 (47%) | .65 |
Significant P values are shown in boldface.
HCT, hematopoietic cell transplantation; No., number; PMBL, primary mediastinal large B-cell lymphoma; tFL, transformed follicular lymphoma.